Edition:
India

Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26


Thursday, 1 Mar 2018 

March 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS.CONCERT PHARMACEUTICALS INC - CTP-543 ON TRACK TO REPORT TOPLINE PHASE 2A RESULTS IN ALOPECIA AREATA BY YEAR-END.CONCERT PHARMACEUTICALS INC - NEW NEUROPSYCHIATRIC PRODUCT CANDIDATE POISED TO ENTER CLINICAL DEVELOPMENT IN 2018.CONCERT PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.26.CONCERT PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG COHORTS OF CTP-543 PHASE 2A TRIAL IN Q4 OF 2018.CONCERT PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, TOTALED $203.2 MILLION VERSUS $96.2 MILLION AS OF DECEMBER 31, 2016.CONCERT PHARMACEUTICALS INC - EXPECTS ITS CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DECEMBER 31, 2017 TO BE SUFFICIENT TO FUND COMPANY INTO 2021. 

Company Quote

9.71
-0.27 -2.71%
23 Aug 2019